KLK2 and neoplasm: Nonetheless, other antigens such as STEAP1/2, KLK2, EpCAM, B7-H3, nfP2X7, NKG2DL, F77 are emerging as promising candidates for CAR-T cell therapy, as they are predominantly expressed in PCa and associated with tumor proliferation and immune evasion.